Keratin 17 Expression Predicts Poor Clinical Outcome in Patients With Advanced Esophageal Squamous Cell Carcinoma.
Aged
Aged, 80 and over
Disease-Free Survival
Esophageal Neoplasms
/ metabolism
Esophageal Squamous Cell Carcinoma
/ metabolism
Female
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Keratin-17
/ biosynthesis
Male
Middle Aged
Neoplasm Proteins
/ biosynthesis
Predictive Value of Tests
Retrospective Studies
Survival Rate
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
26
02
2020
accepted:
23
04
2020
pubmed:
20
6
2020
medline:
30
10
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
The major roles of keratin 17 (K17) as a prognostic biomarker have been highlighted in a range of human malignancies. However, its relevance to esophageal squamous cell carcinoma (ESCC) remains unexplored. In this study, the relationship between K17 expression and clinicopathologic parameters and survival were determined by RNA sequencing (RNA-Seq) in 90 ESCCs and by immunohistochemistry (IHC) in 68 ESCCs. K17 expression was significantly higher in ESCC than in paired normal tissues at both the messenger RNA and protein levels. K17 messenger RNA and staining by IHC were significantly correlated with aggressive characteristics, including advanced clinical stage, invasion depth, and lymph node metastases; and were predictive of poor prognosis in advanced disease patients. Furthermore, K17 expression was detected by IHC in high-grade premalignant lesions of the esophageal mucosa, suggesting that K17 could also be a biomarker of dysplasia of the esophageal mucosa. Overall, this study established that K17 is a negative prognostic biomarker for the most common subtype of esophageal cancer.
Identifiants
pubmed: 32554975
pii: 00129039-202102000-00010
doi: 10.1097/PAI.0000000000000862
doi:
Substances chimiques
KRT17 protein, human
0
Keratin-17
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
144-151Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
L.F.E.-H. and K.R.S. are consultants for KDx Diagnostics Inc. The remaining authors declare no conflict of interest.
Références
Gu L, Sang M, Li J, et al. Expression and prognostic significance of MAGE-A11 and transcription factors (SP1,TFCP2 and ZEB1) in ESCC tissues. Pathol Res Pract. 2019;215:152446.
Huang Y, Guo W, Shi S, et al. Evaluation of the 7th edition of the UICC-AJCC tumor, node, metastasis classification for esophageal cancer in a Chinese cohort. J Thorac Dis. 2016;8:1672–1680.
Qian Z, Wei B, Zhou Y, et al. PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma. BMC Cancer. 2019;19:585.
Wang B, Liang T, Li J. Long noncoding RNA LINC01296 is associated with poor prognosis in ESCC and promotes ESCC cell proliferation, migration and invasion. Eur Rev Med Pharmacol Sci. 2018;22:4524–4531.
Gupta V, Coburn N, Kidane B, et al. Survival prediction tools for esophageal and gastroesophageal junction cancer: a systematic review. J Thorac Cardiovasc Surg. 2018;156:847–856.
Yu J, Zheng Y, Han X, et al. Three-gene immunohistochemical panel predicts progression and unfavorable prognosis in esophageal squamous cell carcinoma. Hum Pathol. 2019;88:7–17.
Wu H, Liu C, Xu M, et al. Prognostic value of the number of negative lymph nodes in esophageal carcinoma without lymphatic metastasis. Thorac Cancer. 2018;9:1129–1135.
Yang Y, Huang X, Zhou L, et al. Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma. BMC Cancer. 2019;19:526.
Escobar-Hoyos LF, Yang J, Zhu J, et al. Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker. Mod Pathol. 2014;27:621–630.
Roa-Peña L, Leiton CV, Babu S, et al. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Sci Rep. 2019;9:11239.
Mockler D, Escobar-Hoyos LF, Akalin A, et al. Keratin 17 Is a prognostic biomarker in endocervical glandular neoplasia. Am J Clin Pathol. 2017;148:264–273.
Bai JDK, Babu S, Roa-Peña L, et al. Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas. Hum Pathol. 2019;94:40–50.
Regenbogen E, Mo M, Romeiser J, et al. Elevated expression of keratin 17 in oropharyngeal squamous cell carcinoma is associated with decreased survival. Head Neck. 2018;40:1788–1798.
Merkin RD, Vanner EA, Romeiser JL, et al. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor–negative/human epidermal growth factor receptor-2–negative breast cancer. Hum Pathol. 2017;62:23–32.
Kim K, Lee HW, Chae SW, et al. Cytokeratin 17 expression is associated with poor prognosis in gallbladder adenocarcinoma. Appl Immunohistochem Mol Morphol. 2017;25:346–350.
Babu S, Mockler DC, Roa-Peña L, et al. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia. Mod Pathol. 2019;32:717–724.
McGowan KM, Coulombe PA. Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development. J Cell Biol. 1998;143:469.
Hobbs RP, Batazzi AS, Han MC, et al. Loss of keratin 17 induces tissue-specific cytokine polarization and cellular differentiation in HPV16-driven cervical tumorigenesis in vivo. Oncogene. 2016;35:5653–5662.
Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol. 2008;129:705–733.
Zhang J, Wang K, Zhang J, et al. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res. 2011;10:2863–2872.
Du Q, Yan W, Burton VH, et al. Validation of esophageal squamous cell carcinoma candidate genes from high-throughput transcriptomic studies. Am J Cancer Res. 2013;3:402–410.
Han G, Wu Z, Zhao N, et al. Overexpression of stathmin plays a pivotal role in the metastasis of esophageal squamous cell carcinoma. Oncotarget. 2017;8:61742–61760.
Liu Z, Yu S, Ye S, et al. Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma. J Proteomics. 2020;211.
Escobar-Hoyos LF, Shah R, Roa-Peña L, et al. Keratin-17 promotes p27KIP1 nuclear export and degradation and offers potential prognostic utility. Cancer Res. 2015;75:3650–3662.
He S, Peng J, Li L, et al. High expression of cytokeratin CAM5.2 in esophageal squamous cell carcinoma is associated with poor prognosis. Medicine (Baltimore). 2019;98:e17104.
Shang L, Liu H-J, Hao J-J, et al. A panel of overexpressed proteins for prognosis in esophageal squamous cell carcinoma. PLoS One. 2014;9:e111045.
Wang C, Wang J, Chen Z, et al. Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. Chin J Cancer. 2017;36:65.
Qi Y-J, Chiu J-F. Proteomic Study of Esophageal Squamous Cell Carcinoma. Proteomics: Human Diseases and Protein Functions. China: InTech; 2012:20.
Rickman DS, Millon R, De Reynies A, et al. Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene. 2008;27:6607–6622.
Cohen-Kerem R, Rahat MA, Madah W, et al. Cytokeratin-17 as a potential marker for squamous cell carcinoma of the larynx. Ann Otol Rhinol Laryngol. 2004;113:821–827.
Khanom R, Nguyen CTK, Kayamori K, et al. Keratin 17 is induced in oral cancer and facilitates tumor growth. PLoS One. 2016;11:e0161163.
Chen X-X, Zhong Q, Liu Y, et al. Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. Nat Commun. 2017;8:524.
Wang GQ, Abnet CC, Shen Q, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 2005;54:187–192.